Citius Oncology grants CEO options on 1M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Citius Oncology, Inc. (CTOR) granted Chief Executive Officer Leonard L. Mazur options covering 1,000,000 common shares on November 9, 2026, at an exercise price of $0.5495 per share, expiring November 9, 2036. The options vest one-third on each of the first, second and third anniversaries, subject to his continuous service to Citius Oncology or a related entity on each applicable vesting date. The report also lists two other direct option positions covering 800,000 and 3,700,000 shares, and 1,700,000 directly held common shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 1,000,000 | $0.00 | $0.00 |
| Holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F3. These options vested over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Key Figures
Key Terms
Continuous Service technical
vest financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did CTOR's CEO receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.